NCT06298318

Brief Summary

The goal of this double-blinded, randomized trial is to investigate the effects of acute binge drinking on liver function, liver fat content, and lipid metabolism in healthy young subjects. The main questions it aims to answer are: 1\. If acute binge drinking could alleviate liver injury and hepatic steatosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Apr 2024

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 1, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

March 7, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

April 27, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 19, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 18, 2024

Completed
Last Updated

January 22, 2025

Status Verified

January 1, 2025

Enrollment Period

5 months

First QC Date

November 1, 2023

Last Update Submit

January 16, 2025

Conditions

Keywords

Acute alcohol intakeLiver

Outcome Measures

Primary Outcomes (3)

  • hepatic function change

    Research blood hepatic function include:Alanine Aminotransferase in U/L;Aspartate Aminotransferase in U/L;Gamma-Glutamyltransferase in U/L;Alpha-Fucosidase in U/L;Alkaline Phosphatase in U/L;cholinesterase in U/L;Lactate Dehydrogenase Enzyme in U/LTBIL in μmol/L, direct bilirubin in μmol/L, indirect bilirubin in μmol/L, and total bile acid in μmol/L

    day1-2 of each 0 hour and 1hour and 5hours and 12 hours and 24 hours

  • Hepatic fibrosis change

    Research blood hepatic fibrosis include:Hyaluronicacid in ng/mL;Laminin in ng/mL;type # in ng/mL;precollagen in ng/ mL;type # collagen in ng/mL;Fibronect in ng/mL

    day1-2 of each 0 hour and 1hour and 5 hours and 12 hours and 24 hours

  • Lipid metabolism change

    Research blood Fat metabolism include:Triglycerides in mmol/L;HDL-Cholesterol in mmol/L;LDL--Cholesterol in mmol/ L;Apolipoprotein A in mmol/L;Apolipoprotein B in mmol/L;Lipoprotein(a) in mmol/L

    day1-2 and of each 0 hour and 1hour and 5 hours and 12 hours and 24 hours

Secondary Outcomes (2)

  • Ethanol concentration

    day1-2 of each 0 hour and 1hour and 5hours and 12 hours and 24 hours

  • Acetaldehyde concentration

    day1-2 of each 0 hour and 1hour and 5hours and 12 hours and 24 hours

Other Outcomes (1)

  • Fecal metabolites

    day1-2 of each 0 hour and 24 hours

Study Arms (2)

Control group

PLACEBO COMPARATOR

BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of water; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of water.

Other: water

vodka group

EXPERIMENTAL

BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.

Other: Vodka

Interventions

VodkaOTHER

BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.

vodka group
waterOTHER

equal amount of non-alcoholic beverages with the same taste and colour but without alcohol

Control group

Eligibility Criteria

Age18 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • male aged 18-30 years;
  • body mass index (BMI) ranging from 18.5 to 28 kg/m²;
  • having prior experience with binge drinking or hangovers, as assessed using the Personal Assessment of Maximum Drinking Capacity Survey Questionnaire

You may not qualify if:

  • with alcohol intolerance or alcohol dependence;
  • with serious health conditions, such as liver, kidney, cardiovascular, or gastrointestinal diseases;
  • vegetarians;
  • smokers;
  • with a history of drug use, including antihistamines, antihypertensives, antidiabetics, anxiolytics, and central nervous system depressants;
  • who had used antibiotics within two weeks prior to the trial;
  • who had consumed alcohol, alcoholic beverages or alcohol-containing foods within one week before the trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhejiang Chinese Medical University

Hangzhou, Zhejiang, 310053, China

Location

Related Publications (2)

  • Lee MH, Kwak JH, Jeon G, Lee JW, Seo JH, Lee HS, Lee JH. Red ginseng relieves the effects of alcohol consumption and hangover symptoms in healthy men: a randomized crossover study. Food Funct. 2014 Mar;5(3):528-34. doi: 10.1039/c3fo60481k.

    PMID: 24458173BACKGROUND
  • Kim H, Kim YJ, Jeong HY, Kim JY, Choi EK, Chae SW, Kwon O. A standardized extract of the fruit of Hovenia dulcis alleviated alcohol-induced hangover in healthy subjects with heterozygous ALDH2: A randomized, controlled, crossover trial. J Ethnopharmacol. 2017 Sep 14;209:167-174. doi: 10.1016/j.jep.2017.07.028. Epub 2017 Jul 24.

    PMID: 28750942BACKGROUND

MeSH Terms

Conditions

Binge DrinkingFatty Liver

Interventions

Water

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersAlcohol DrinkingDrinking BehaviorBehaviorMental DisordersLiver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

HydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Study Officials

  • guiiqin sun

    Zhejiang Chinese Medical University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: not involve drug or biologic products
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

November 1, 2023

First Posted

March 7, 2024

Study Start

April 27, 2024

Primary Completion

September 19, 2024

Study Completion

November 18, 2024

Last Updated

January 22, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Protect volunteers' personal health data and personal privacy

Locations